The pharmaceutical industry is undergoing an era of innovation and change. Over the next few years, companies will need to ...

Against this backdrop, the Leadership Summit will return to CPHI Milan in 2026, bringing senior pharmaceutical ...

AZ's $2 billion investment – at $18.36 per share – puts the UK-headquartered company in the driving seat to pair its ...

Sustainability in Life Sciences Summit is the premier meeting point for sustainability, ESG, corporate responsibility, ...

A new event at CPHI Milan 2026 hopes to inspire delegates to collaborate on some of the pharmaceutical industry’s biggest ...

MSD has signed a global license agreement for a KRAS G12D inhibitor from China's SciBrunch Therapeutics, paying $400 million ...

Other candidates in its pipeline include injectable GIP/GLP-1 agonist enicepatide, injectable amylin analogue petrelintide, ...

Patients with fibrodysplasia ossificans progressiva (FOP) in the US will soon have the option of treatment with another daily ...

A team from the Garvan Institute of Medical Research in Darlinghurst, New South Wales, have used an emerging form of genetic ...

The first product from AbbVie's $8.7 billion takeover of Cerevel two years ago – Parkinson's disease therapy tavapadon – has ...

MSD and Daiichi Sankyo's regulatory efforts for their antibody-drug conjugates (ADCs) for cancer have stuttered again, with a ...

A healthcare breakthrough may be supported by compelling evidence and formally recommended for use, but patients will only ...